Completed PHASE3 INTERVENTIONAL 2-arm NCT06383819

Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Sponsor: NPO Petrovax

Conditions Fibrosis Lung Disease With Polymyositis Lung Diseases, Interstitial Lung; Disease, Interstitial, With Fibrosis Post-Acute COVID-19 Syndrome

Interventions Longidaza® Placebo

Updated 5 times since 2024 Last updated: May 28, 2025 Started: Apr 8, 2022 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06383819, this PHASE3 trial focuses on Fibrosis and Lung Disease With Polymyositis and remains completed. Sponsored by NPO Petrovax, it has been updated 5 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Jun 2025 — Sep 2025 [monthly]

Completed PHASE3
Sep 2024 — Jun 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2024 — Jul 2024 [monthly]

Completed PHASE3

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NPO Petrovax

Data source: NPO Petrovax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aramil, Russia , Chelyabinsk, Russia , Izhevsk, Russia , Kazan', Russia , Kemerovo, Russia , Kirov, Russia , Moscow, Russia , Novosibirsk, Russia , Perm, Russia , Saint Petersburg, Russia and 6 more locations